A substantial number of individuals with type 2 diabetes mellitus (T2DM) demonstrate a predominance of small dense low-density lipoprotein (sdLDL), which is associated with an increased risk of cardiovascular disease (CVD). In some cases, sdLDL persists after treatment with a statin to reduce levels of LDL. The effect of the addition of a thiazolidinedione, rosiglitazone (RSG) (4 mg/day or 8 mg/day) to statin therapy on LDL phenotype and C reactive protein (CRP) levels was investigated in a 12week, placebo-controlled study of 72 T2DM patients who were well controlled and on a statin, but who had persistently predominant sdLDL.
Introduction
Cardiovascular disease (CVD) is a major cause of morbidity and mortality in subjects with type 2 diabetes mellitus (T2DM). 1 One of the leading contributors to CVD in T2DM patients is diabetic dyslipidaemia, characterised by low levels of high-density lipoprotein (HDL)-cholesterol, a high proportion of small dense low-density lipoprotein (sdLDL) particles and relatively high triglycerides.
Small dense LDL has been reported to be the predominant form of LDL in 37% of women 2 and 53% of men 3 with T2DM, compared with 5% of women and 28% of men in the non-diabetic population. 2, 3 Thus, sdLDL is the predominant form of LDL in approximately half the population with diabetes. The increased prevalence of sdLDL in T2DM patients has been partly attributed to central obesity and insulin resistance, associated with the presence of triglyceride-rich, very low-density lipoproteins (VLDLs) and altered activities of enzymes involved in lipoprotein metabolism. 4 A predominance of large buoyant LDL, rather than sdLDL, as the major LDL subfraction is considered to be desirable with respect to reducing atherosclerotic risk. Along with total apolipoprotein (apo) B-containing particles, sdLDL has been associated with a substantial increase in CVD risk. 5 While the independent association between sdLDL particles and CVD has been questioned, 6 a number of clinical and epidemiology studies 5,7-10 have indicated that LDL-particle size and density are associated with the long-term risk of ischaemic heart disease (IHD) and carotid intima-media thickness. Decreasing the number of sdLDL particles has been shown to be a stronger predictor of regression of coronary stenosis than lowering LDL-cholesterol levels. 7 Furthermore, sdLDL is a better predictor of coronary heart disease (CHD) than other lipid parameters (including LDL apo B and HDL-cholesterol) in patients with T2DM 11 and is associated with other metabolic disorders, including insulin resistance, which increase CVD risk.
The increased atherosclerotic risk associated with sdLDL, as compared with large buoyant LDL, is thought to be due to their increased susceptibility to oxidation and greater ease in penetrating the vascular wall, resulting in vascular wall injury and initiation of an inflammatory response. Moreover, mildly elevated C-reactive protein (CRP) 12 is often observed in T2DM and in obese patients. Patients who demonstrate higher CRP and a predominance of sdLDL have an increased likelihood of developing CHD compared with those with lower CRP levels and similar sdLDL phenotype. 13 Thus, a therapeutic approach that reduces both the number of sdLDL particles and the level of CRP could reduce the risk of CVD.
Statin therapy has been shown to reduce total cholesterol, including sdLDL particles, 5, 14 and CRP levels as well as the risk of CHD. 15 However, patients with diabetes on statin therapy still bear a higher risk of developing CVD compared with non-diabetic patients, 14, 16, 17 possibly because statins such as simvastatin 18, 19 lower LDL-cholesterol but have limited impact on switching the more atherogenic sdLDL to the less atherogenic large buoyant LDL phenotype. In a previous study by our group, rosiglitazone (RSG), a thiazolidinedione (TZD) insulin sensitiser, was shown to improve glycaemic control as well as increase LDL-particle buoyancy and HDLcholesterol, though there was also a mild increase in LDLcholesterol. 20 In this previous study, the addition of a statin to RSG therapy decreased LDL-cholesterol and apo B but did not alter the effects of RSG on LDL-particle buoyancy. However, this sequence of drug administration is not the typical treatment regimen: statins are usually prescribed first. Therefore, the purpose of the present study was to investigate the more typical clinical situation by determining the effects of the addition of RSG in T2DM patients whose LDLcholesterol is already well controlled on statin therapy but who continue to present with an sdLDL phenotype. This would be expected to represent a substantial number of subjects with T2DM. Additionally, the study investigated the effect of RSG on an inflammatory marker (CRP) and a fibrinolytic marker (plasminogen activator inhibitor-1 [PAI-1]) that are also associated with an increase in CVD risk. 21 
Methods

Study design
This was a 12-week, double-blind, placebo-controlled study. After a screening visit, eligible subjects were randomised to double-blind study medication (for the treatment period) to one of three treatment groups in a 1:2:2 ratio. The groups were: placebo plus continuation of statin (PS), RSG 4 mg plus continuation of statin (4RS) or RSG 8 mg plus continuation of statin (8RS).
This was a multicentre (a total of 23 centres) study con-ducted in the US. Written, informed consent was obtained from each subject prior to enrolment. The protocol and statement of informed consent were approved by a human subjects committee prior to initiation at each centre.
Subjects
Individuals with T2DM, aged 18-75 years, with LDL-cholesterol < 160 mg/dL (4.14 mmol/L), triglyceride < 500 mg/dL (5.64 mmol/L), fasting plasma glucose (FPG) < 160 mg/dL (8.8 mmol/L) and with a predominance of dense LDL, as defined by LDL Relative flotation (Rf) <0.263 (equivalent to < 255Å), were eligible for inclusion. Eligible subjects were required to be on a stable dose of statin therapy, as well as on either diet/exercise alone or a stable dose of metformin for their glycaemic control, for at least two months prior to study entry. Subjects were excluded if they had a history of hypertriglyceridaemia-induced pancreatitis or triglyceride concentration > 1,000 mg/dL (11.29 mmol/L), any known clinically significant hepatic disease, renal disease, severe CHD, congestive heart failure which required pharmacological intervention, uncontrolled hypertension (> 180/110 mmHg), or were currently using fibrate or any hypoglycaemic agents other than metformin within the three months prior to the screening visit.
Laboratory analysis
Total cholesterol, triglyceride, LDL-cholesterol, HDL-cholesterol, apo B, FPG and HbA 1C were measured, as described previously.
Density gradient ultracentrifugation (DGUC) and LDL Rf Samples were separated by non-equilibrium density gradient ultracentrifugation and fractioned into 38 fractions (North West Lipid Research Laboratories [NWLRL], Seattle, WA). 22 Rf was derived by dividing the number of the fraction containing the highest cholesterol content by the total number of fractions (38 fractions). An Rf <0.263 (equivalent to <255Å) was considered to reflect a predominance of sdLDL particles.
Gradient gel electrophoresis (GGE)
Non-denaturing polyacrylamide gradient gel electrophoresis (from 2% to 16%) carried out in the Brunzell laboratory (Seattle, WA) was used to characterise the LDL particle size. 23 Phoretix software was used to determined LDL size.
CRP and other CV biomarkers
High-sensitivity CRP was assayed by nephelometry. PAI-1 antigen and activity were measured by enzyme-linked immunosorbent assay (ELISA) and a chromolise PAI-1 immunoactivity kit, respectively. CRP and PAI-1 antigen and activity were assayed by Pharmacodynamics Endpoint Research Laboratory (Philadelphia, PA). All other laboratory parameters were assayed by Quest Laboratory (Hercules, CA). All lipid-related assays were performed by NWLRL (Seattle, WA).
Data analysis
The sample size was estimated based on change from base-line in LDL Rf, with a standard deviation (SD) of 0.023. Assessments of efficacy were based on subjects who completed the study. All randomised subjects who received at least one dose of double-blind study medication were assessed for clinical safety and tolerability. A paired t-test was used for comparisons of the mean changes from baseline to week 12 in all efficacy parameters. Treatment differences were assessed using ANCOVA adjusted by baseline values and gender as covariates in the model. Variables (total cholesterol, triglyceride, insulin resistance, CRP, PAI-1 antigen and PAI-1 activity) were log transformed prior to analyses due to skewed distributions. Insulin resistance was estimated by the homeostasis model assessment (HOMA) based on the following calculation:HOMA IR= (fasting insulin*FPG)/ 22.5. 24 For the difference plots comparing the change in the lipoprotein density distribution of the treated (8RS) group compared with that of the placebo group (PS), 95% confidence intervals were calculated. If the interval passes through the zero point of the graph, the difference is not statistically significant.
Results
Study population
Ninety-eight subjects with T2DM and on a statin were screened for eligibility, of whom 72 were randomised to the treatment groups, and 69 completed the study. Initially, after randomisation, there were 14 subjects in the PS group, 29 in the 4RS group and 29 in the 8RS group. After the withdrawals there remained 13 in the PS group, 27 in the 4RS group and 29 in the 8RS group. One withdrawal was due to an adverse event and two were due to protocol violations. Demographic and baseline characteristics were generally well matched between the groups (table 1) . At baseline, mean LDL-cholesterol levels were under 100 mg/dL (2.6 mmol/L) in all three treatment groups after a minimum of two months of statin therapy. However, the LDL particles were small (<255Å) and dense (LDL Rf <0.263) (table 2a) . Of the 72 randomised subjects, 22 subjects were diabetic drug-naïve and 50 subjects were on metformin, with seven of these subjects (7/14, 50%) in PS, 22 (22/29, 76%) in 4RS and 21 (21/29, 72%) in 8RS, respectively. The statins used in the study were atorvastatin (55.6%), simvastatin (25.0%), lovastatin (9.7%) and pravastatin (9.7%). However, the type and dose of statin used prior to study entry did not form part of the randomisation. No change in statin dose was allowed during the study.
Effects on lipid profiles
After 12 weeks of treatment with RSG, a significant increase in total cholesterol (12.2%, p=0.004) and LDL-cholesterol (11.2%, p=0.02) was observed in the 8RS group (table 2a) . There were no significant changes from baseline in total apo B, LDL apo B, HDL-cholesterol or triglyceride in any of the treatment groups (table 2a) , and there were no significant treatment differences between RSG and PS in any of these parameters (table 3) .
After separating LDL into subfractions by DGUC, it was observed that the addition of RSG (4 mg and 8 mg) to statin therapy increased the LDL Rf from baseline by 0.006 (p=0.27) and 0.014 (p=0.003) respectively (table 2a, figure  1a ). The increase in the Rf of the 8RS group was significantly different from that of PS by +0.014 (p=0.03; table 3 ). In contrast, LDL Rf in the PS group demonstrated little change from baseline (0.003, p=0.54). Thus, the LDL-cholesterol peak shifted significantly towards a more buoyant density (figure 1a, presented for 8RS only) relative to the baseline distribution. From the DGUC results it can be seen that addition of RSG 4 and 8 mg to statin therapy significantly increased LDL cholesterol in the large buoyant LDL fractions 10-19 as well as in the intermediate-density lipoprotein (IDL) fractions. However, the apparent decrease in LDL cholesterol in the dense LDL fractions 7-9 relative to that of the PS group did not reach significance (figure 1b). RSG did not change the cholesterol content significantly in the HDL fractions.
The LDL peak particle size, as measured by GGE, increased significantly from 252.8Å at baseline to 257Å at week 12 (+4.2Å, p=0.001) in the 8RS group (LDL peak particle size was not measured in the 4RS group) (table 2a) . There was no significant change in the PS group. The increase in LDL particle size in the 8RS group was also significantly different from that of the PS group (Δ=+3.8Å, p=0.04) (table 3) .
Inflammatory markers
CRP levels were found to be relatively high at baseline in this cohort (table 2b) . Addition of RSG 4 and 8 mg to statin therapy significantly reduced levels of CRP by 36.5% (p=0.001) and 39.5% (p=0.02) from baseline, respectively, whereas ORIGINAL ARTICLE The fibrinolytic marker, PAI-1 antigen and activity fell from baseline in all treatment groups. Only the 8RS group had a significant decrease in PAI-1 antigen from baseline to study end (18.3%, p=0.04), but there was no treatment effect (table 2b and table 3) . Addition of RSG 4 and 8 mg to statin therapy reduced HOMA-estimated insulin resistance significantly from baseline by 33.5% (p=0.0001) and 39.9% (p=0.002), respectively, whereas there was no significant change in the PS group (table 2b) . Compared with the PS group, insulin resistance fell in both RSG plus statin groups; however, the treatment difference did not reach statistical significance.
Glucose metabolic indices
Safety and tolerability
Addition of RSG to statin was generally well tolerated. In the 4RS group, one subject reported weight gain (2.9 kg) and three subjects reported mild-to-moderate oedema, which resulted in one withdrawal from the study. In the 8RS group, one subject reported an episode of hypoglycaemia and one a maculopapular rash; neither event led to withdrawal. Body mass index (BMI) was significantly increased in the RSG treatment groups compared with the PS groups (0.71 kg/m 2 in 4RS and 0.70 kg/m 2 in 8RS, respectively). There were no reports of congestive heart failure or anaemia. Two subjects in PS experienced non-fatal serious adverse events: one gastroenteritis and the other a moderate cerebrovascular acci-dent. There were no reports of serious adverse events in the RSG treatment groups.
Discussion
Diabetic dyslipidaemia is considered a predictor of increased CVD risk. In order to improve clinical outcomes, recent American Diabetes Association guidelines have emphasised that while treating hyperglycaemia, treatment of diabetic dyslipidaemia (including sdLDL) should be considered an essential part of clinical management of T2DM.
In this study, after at least two months on a constant dose of statin to stabilise baseline LDL-cholesterol, the addition of RSG significantly increased LDL peak particle buoyancy (Rf) and LDL peak particle size, which could suggest a shift in LDL phenotype from small dense, atherogenic particles to larger, more buoyant, less atherogenic particles. However, since the decrease in sdLDL observed in the 8RS group did not reach significance, we are unable to state that a shift in LDL density occurred. We cannot tell whether the increase in buoyant LDL is due to a shift in particle distribution and/or a selective increase in the cholesterol content of the buoyant ORIGINAL ARTICLE n represents the number of subjects having values at both baseline and study end; *Indicated the test statistic was significant using paired t-test.
To convert plasma glucose from mg/dL to mmol/L, multiply by 0.055 Key: CRP = C-reactive protein; CV = coefficient of variation; FPG = fasting plasma glucose; HOMA IR = homeostasis model assessment estimates of insulin resistance; PAI-1 = plasminogen activator inhibitor-1; PS = placebo plus statin; 4RS = rosiglitazone 4 mg plus statin; 8RS = rosiglitazone 8 mg plus statin; SD = standard deviation LDL fractions when an increase in total LDL cholesterol occurs as a result of RSG treatment. There was no increase in LDL apo B or total apo B, indicating that LDL particle number did not increase but, rather, that particles gained cholesterol. The increase in LDL particle size in the RSG group from 252.8Å at baseline to 257Å after treatment may be significant, as it has recently been reported in a large cohort that LDL cholesterol in particles greater than 260Å was not associated with ischaemic heart disease whereas LDL cholesterol in particles less than 255Å, as a proxy of sdLDL, was strongly and independently associated with IHD. 5 However, one cannot suggest that it is desirable to have an increase in buoyant LDL without a significant decrease in dense LDL, particularly when accompanied by an increase in IDL cholesterol. T2DM patients with obesity often demonstrate lowgrade inflammation associated with mildly elevated CRP. Regardless of the LDL-cholesterol level, CRP lowering has been associated with attenuation of atheroma progression 15 and a reduction of CVD risk in patients treated with statin therapy. Although statins have demonstrated anti-inflammatory effects, 15, 25 in this study, despite two months of statin therapy, baseline CRP levels remained relatively high, consistent with ongoing low-grade inflammation. The addition of RSG to the existing statin therapy in T2DM patients produced a significant further reduction in CRP that was not seen in the placebo group. This suggests that TZDs may mediate the decrease in CRP through a mechanism different from that of statins. Regardless of the mechanism involved, the reduction of CRP by TZDs could be significant in lowering the CVD risk by preventing the progression of atherosclerosis.
Both statins and RSG have been reported to reduce haemostatic factor PAI-1 antigen and activities. 26, 27 In this study, PAI-1 antigen and activity fell in all treatment groups; ORIGINAL ARTICLE To convert cholesterol values from mg/dL to mmol/L, multiply by 0.02586 Key: DGUC = density gradient ultracentrifugation; RSG = rosiglitazone however, only subjects in the 8RS group had a significant decrease in PAI-1 antigen from baseline, and no treatment effect was observed. This raises doubts as to whether TZDs have any further effects beyond statins in reducing PAI-1 antigen production and activation in patients with T2DM.
The long-term effect of TZDs on reducing risk of CVD has been challenged since the publication of the results of the PROactive study, 28 which included T2DM patients with a history of CVD. Pioglitazone treatment was associated with an improvement in lipids and glucose, and a moderate reduction of CVD events with no additional beneficial effect in patients already on a statin. The primary composite outcome for the study was negative. Perhaps it would be beneficial to administer TZDs at a much earlier stage of disease, before the onset of clinical CVD, to take advantage of their effects on the metabolic profile and inflammation while avoiding the disadvantage of developing oedema and heart failure in individuals who are less at risk. Although effects on lipids have been reported differently between RSG and pioglitazone, both agents have shown similar properties of changing LDL particle density and reducing inflammation biomarkers. The benefits of TZDs should be tested in future primary prevention studies to assess accurately the relationship of TZDs with CVD incidence in the general T2DM population.
There are several limitations to this study. The type and dose of statin therapy prior to entry was not a factor relevant to stratification at the time of randomisation, which could potentially confound the analyses of lipids and inflammation markers. This study was relatively small in size and therefore not powered for some analyses. The relatively short duration may have limited the ability to determine an effect on parameters such as HbA 1C , but was more than adequate for determination of effects on plasma lipids and LDL particle size. Also, the lack of a significant decrease in sdLDL in the treated group (8RS) relative to placebo may be due to the relatively small number of subjects studied. An investigation including a greater number of subjects might demonstrate a significant decrease in sdLDL as a result of RSG treatment added to statin therapy.
In summary, this study suggests that RSG increases buoyant LDL and mean LDL size in the typical clinical situation where patients are already on statin therapy and continue to have sdLDL. A TZD and a statin as combination therapy for patients with T2DM may help to improve a number of CVD risk factors, including CRP, insulin resistance and FPG. However, since a decrease in sdLDL could not be determined and an increase in IDL was observed, the results must be interpreted with caution. Whether the beneficial effects of TZDs observed in this short-term study outweigh the adverse effects of TZDs on weight gain, oedema and increased LDL-and IDL-cholesterol, and whether they result in a reduction in CVD risk in the long term, need to be validated in further outcome studies, especially in early intervention outcome studies with a greater number of subjects. Early TZD and statin combination therapy may have the potential to improve CV outcomes for patients with T2DM, but the changes in total LDL and IDL must be investigated further.
